BBOT Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -6.56%, SMA50 -12.25%, SMA200 -8.8%). The stock’s 14-day RSI is 41.26 (neutral), while the ATR of 0.81 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -31.07% below its high and over 20.59% above its low. Average 10-day trading volume of 303.48 thousand shares is in line with the 3-month average of 314.74 thousand, indicating normal recent market interest.

BridgeBio Oncology Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $11.91. This means the shares are trading below this model’s fair value.

BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) closed at $7.66 USD, losing -$0.20 (-2.54%) from the previous close of $7.86. The stock is currently trading near its 52-week low $7.60 and $14.87. With a market capitalization of about $613.66 million, BridgeBio Oncology Therapeutics Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.22). Key stats such as the average daily volume over the past year has been around 316.59 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, BridgeBio Oncology Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Eli Wallace, the company employs approximately 62 people and listed since August 12, 2025. BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors.

Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $29.00 to $20.00. The high target offers 278.59% upside. The low target suggests 161.1% downside. The mean target is $24.36. This offers 218.02% upside. BridgeBio Oncology Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended March 05, 2026, missed forecasts by -22.6%. The prior quarter beat by 169.63%. Over the last six quarters, Apple has recorded several small beats. These include 169.63% in November 12, 2025.

Our AI price prediction model suggests that BridgeBio Oncology Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.74%, with price expected at $7.22 by May 22, 2026, within a range of $6.90 to $7.56 3-Month Outlook: Projected fall of -25.2%, reaching $5.73 by August 06, 2026, with a range of $5.54 to $5.92. 1-Year Outlook: Projected gain of 28.72%, with price at $9.86 by May 07, 2027, within a range of $9.71 to $10.03.

BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) shares are flat -8.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows BridgeBio Oncology Therapeutics Inc. trading at a premium to the broader market with a P/E of -1.79. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.36, suggesting 218.02% upside. Our AI forecast model points to short-term weakness (-5.74% over two weeks), a medium-term fall (-25.2% over three months), and a longer-term gain (28.72% over one year), with expected trading ranges indicating moderate volatility.

BridgeBio Oncology Therapeutics Inc. trades at a P/E ratio of -1.79, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.58 suggesting the stock is closer to book value. The P/FCF stands at -6.47, also below market averages.